| 货号 | 18722-1mg |
| 描述 | Janus-associated kinases (JAKs) are cytoplasmic tyrosine kinases that are required for activating the signaling of certain cytokines and growth factor receptors. Oclacitinib is an orally bioavailable, broad spectrum JAK inhibitor (IC50s = 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and JAK4, respectively).1 It is specific for JAK isozymes against a large panel of other kinases.2 Oclacitinib blocks cell-based JAK signaling induced by IL-2, IL-4, IL-6, IL-13, or IL-31 with IC50 values ranging from 36 to 249 nM.1 Oral oclacitinib is used against atopic dermatitis with pruritus in dogs.3,4 |
| 别名 | PF 03394197; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Gonzales, A.J.,Bowman, J.W.,Fici, G.J., et al. Oclacitinib (APOQUELr) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Journal of Veterinary Pharmacology and Therapeutics 37(4), 317-324 (2014). 2.Kerkhofs, T.M.A.,Ettaieb, M.H.T.,Hermsen, I.G.C., et al. Developing treatment for adrenocortical carcinoma. Endocr.-Relat.Cancer 22(6), R325-R328 (2015). 3.Olivry, T.,DeBoer, D.J.,Favrot, C., et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet.Res. 11:210, (2015). 4.Cosgrove, S.B.,Wren, J.A.,Cleaver, D.M., et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet.Dermatol. 24(5), (2013). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 337.4 |
| 分子式 | C15H23N5O2S |
| CAS号 | 1208319-26-9 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |